Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed on both and adding here and sub. GNBT is sooooo undervalued currently. Just NGIO alone is worth double of the current shareprice. Thanks for chiming in my friend GNBT will have it's day. :)
Covid 19 is not media hype far from it. GNBT still has a chance for a Vaccine that will curtail the virus.
Fresh from OTC 3/6/2020 Outstanding Shares/Float
O/S 475,000,000
Float 290,162,500
Transfer Agent Verified
https://www.otcmarkets.com/stock/MILV/security
The Rest of GNBT
Buccal Tissue Delivery
Diagnostic Kits
Wound Treatment
Ulcerative Colitis Treatment
Orthopedic Kits
Medical Services Organization (MSO)
BUCCAL TISSUE DELIVERY
This uses a spray to deliver a large molecule, in its test case, insulin, to the blood rich buccal tissue inside the cheek and from there to the blood system. My take has always been that if patients could choose between a needle (even if it is called a pen) and spritzing stuff inside the cheek, they would choose the latter every single time. Pfizer wrote off $2.8 billion on a system that sent insulin into the lungs. Patients didn’t like it, and that was that. But this does not go in the lung.
Pfizer (PFE) didn’t develop Exubera for its write-off potential, so I think the buccal spray’s ultimate value is some multiple of what Pfizer wrote off. Billions.
Generex did Phase I, II, III studies but the FDA wanted more proof. As I understand it from James Anderson M.D. of Generex, who came along after that trial, the study was poorly designed. He and others have improved the spray so that now it only takes 2 or 3 spritzes to get sufficient insulin (as opposed to 10-12), and I am confident that Anderson, former Chief of Medicine at Ely Lilly (an important insulin maker), can design a trial that can gain approval.
DIAGNOSTIC KITS
The company has developed kits that can be used in a doctor’s office to immediately advise patients if they have a disease or not. In China, for example, this may ultimately be approved for home use, so the market could be quite substantial. Kits have been developed for syphilis, malaria, HIV, hepatitis B and C, and now the company is investigating the possibility of a diagnostic kit for coronavirus.
The company has the talent to design a diagnostic kit, but in a company short of funds, I am not clear what kind of resources can be brought to bear. It might be like a university and its graduate students. Learn to write grants, find money.
WOUND TREATMENT
Generex bought Olaregen which has a liquid solution including collagen called Excellagen that is applied to the wound, and it heals faster than other methods. The product was introduced within the last year, and it is just now powering up. Sales for November were reported as $450,000 for November, but it’s on an upward trajectory. This company alone might be worth today’s market cap.
ULCERATIVE COLITIS
This treatment creates a kind of collagen bandage over the inflamed tissue in the colon, allowing it to heal. In development.
ORTHOPEDIC TOOLS AND SURGICAL KITS
Generex bought a company called Pantheon, which makes orthopedic tools and kits. It is starting to generate sales.
MEDICAL SERVICES ORGANIZATION (MSO)
Generex bought a company called Veneto, which provides services to doctors from software to x-rays to accounting. It will be reactivated in the next year.
Diabetes Initiative
In a brilliant move, the company saw that it had a couple of pieces of the diabetes puzzle, with another in the offing, and put together a plan to bring them together. It has the buccal delivery. It has the wound treatment, especially useful for diabetic patients, and it has signed a Letter of Intent to acquire ALTuCELL, in which a father, Gary Harlem, went in search of a cure for diabetes for his son. It is quite a quite clever solution.
Put these things together, plus using their MSO, and creating an HMO together with a few medical practices in Arizona and you have 25,000 to 40,000 diabetic patients who need wound treatment, and can be test subjects for bringing buccal delivery and the diabetes cure on line, and initial buyers of developed products. Positively brilliant.
So even if the insulin companies would rather their patients suffer with needles and pens, Generex can introduce the spray, and there will no way to stop its success.
NGIO Cancer treatment may look like this in the future: You take leronlimab to stop the spread, to stop metastasis and metastasized tumors. Surgery or radiation or CAR-T or other treatment to kill the principal tumor, and followed up with Generex's NGIO's cancer vaccination to prevent recurrence.
Which brings us to Generex, and we begin again with NGIO, which started life with 150 million shares; about another 20 million were added with the recently paid stock dividend, so that would be 170 million shares. Perhaps another 10 million will be added with the IPO. As a point of reference, INO which announced human trials beginning in April, has seen its market cap increase by a staggering $1 billion in the last 9 days to $1.4 billion. If NGIO were to have a vaccine in hand before their planned IPO, I think the pricing would be in the $7-$9 range. Without it, probably more in the $2 to $4 range.
It's cancer possibilities, which could be quite valuable, are completely in the shadow for now, but in the scenario I raised above, it may have a valuable role in the big picture of cancer treatment.
With China on lockdown, and now Italy on lockdown, nations are taking extreme action on the isolation front. Extreme hygiene, self-isolation, and anti-grouping behaviors may reduce the spread of this virus, and may reduce the need for vaccines, which is why work on this should continue, so that vaccines can be made quickly, especially for medical professionals.
While I expect shares will be sold in the IPO, money will start coming in from its virus work. It should be getting $6 million from China. And I presume the U.S. government will be paying such fees, and the countries of the European Union, and the UK, and so on. Given that they have already worked with SARS, which is a coronavirus, they have a leg up. Though if INO is doing human testing in April, it’s not that much of a leg up. With the March 4th collaboration with Epivax, they have probably improved their odds of developing a virus candidate sooner than later.
I expect some good news stories. More fundings. Grants. Whatever. Given GNBT’s previous extensive work in the area, there will probably be good results in studies, and finally, orders for vaccines doses. It could be very big. It’s a sleeper for now with INO and Moderna (MRNA) getting all the attention (and all the market cap gains).
Long time investors have been worn down with as they waited for stock dividends, which were halted for various reasons - potentially illegal selling of restricted stock, regulatory officials. But new investors will probably hit it just right.
But Generex (OTCQB:GNBT) has many other bets. My favorite technology of GNBT has always been the buccal delivery technology, what could be better for diabetic patients than a spritz inside the mouth? It’s a heck of a lot better than a needle. And that unit could ultimately be sold off for billions. Plus it has other possibilities: wound treatment, ulcerative colitis treatment, orthopedic products, medical services organization. My current feeling is to think of CEO Joseph Moscato as a biotech John Malone. Check the market cap. Weigh it. Divide the market cap by all of its possibilities, and it looks ridiculously low to me.
That is a great article Many positives re GNBT and subs
The NGIO/Generex Plan for Vaccine Development
Time is of the essence, and it appears to me that Generex is a very good bet for a first line preventive vaccine for coronavirus. I say a “first line” vaccine because these vaccines may supercharge the body’s immune system making the likihood of death much smaller, but according to Eric von Hofe, patients may still suffer, the point is that likihood of death drops. So perhaps work needs to continue for regular type vaccines, but in the current situation, a pandemic, we need something as soon as we can get it. And a typical vaccine will take probably take a year or more. I think just about everyone would want a “first line” vaccine, or synthetic vaccine, as soon as they could get it.
These are people waiting to show they have the stuff. They are extremely well-motivated. Moscato wants to show that his leadership can lead to products. Same for Eric von Hofe, of NGIO, who has already developed vaccines for avian flu, swine flu, SARS (a coronavirus), but they came too late, and he would like to show his technology can be useful in this kind of situation. Same goes for Anna De Groot of Epivax, who was connected to Generex through NGIO director, Carol Nacy, though it is not entirely a new connection, NGIO’s Eric von Hofe said, “we have known Dr. De Groot and her excellent work on vaccines and the immune system for over 20 years.”
Epivax has the computational tools NGIO needs to nail down some epitope targets. “As soon as the [DNA] sequence was published, I said, ‘could we please analyze this sequence for potential vaccine design?’” says Annie De Groot, an immunologist and co-founder of Rhode Island-based EpiVax. “Three hours later, we had the essential elements for designing a vaccine.” Her desired time frame is a month: You could get into a phase one safety trial within weeks,” De Groot says. “Four weeks at the shortest,” from start to finish.
Generex outlined their strategy in a recent press release. NGIO will use De Groot’s predictions about epitopes to synthesize amino acid strings (peptides) that will be sent to China to test how they respond in the blood of those who have survived the infection, who will have immune cells that have learned how to respond to the infection. They will then see which peptides the immune cells and antibodies are responding to, and that will tell them which hybrid Ii-key peptides they need to trigger the immune system. Then you have the basis for your vaccine.
For the dreamers: Generex’s S-1 suggests a fee of $2 per person. If China has 1.4 billion people, that multiplies out to $2.8 billion. Probably it will take far less to stop the virus, but it could still be in the hundreds of millions.
Though I have contradictory opinions to sort out. De Groot says that manufacture of these vaccines is difficult and expensive, and will be used to protect medical professionals, but von Hofe told me they were not expensive, and I presume they could be used by vast segments of the population. I sent a query to CEO Moscato, who wrote, “Synthetic peptides against the traditional peptides are far far less expensive.”
In any event, medical professionals will get the vaccine first, and perhaps a learning curve will bring down the cost, so that it will be feasible to vaccinate large swaths of the population.
The race is on. Inovio (INO) has said it will begin human trials in April. Moderna (MRNA) is also in the contest, working on an RNA vaccine, which may take longer. But given the relative market caps shown below, I would take it that the market doesn’t even know NGIO (OTCQB:GNBT) is in the race.
https://seekingalpha.com/article/4330919-basket-of-biotechs?utm_medium=email&utm_source=seeking_alpha&mail_subject=cydy-gnbt-a-basket-of-biotechs&utm_campaign=rta-stock-article&utm_content=link-0
A Biotech is emerging.
Correct, did a 5:2 for both GNBT and NGIO in Feb for people who bought prior. NGIO is sitting in my TDA account however still in process and not able to trade finalizing S1. GNBT shares are there, Mgmt retired most shares to do this.
Great BUY/HOLD Have MM Move the price UP
Freakin great doubled my position today :)
1/2ed upper market stocks when they started to tank/Covid 19 ck GNBT did much DD on that/Undervalued
took out 400K
Talked about MILV on the other Discord Channel last evg :()
Bought 200K today Go MILV oops 450K
NuGenerex Immuno-Oncology (formerly Antigen Express), a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines based on the CD-4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) is being spun out of Generex as a separate, independent public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer. Current S1 Filing for the NASDAQ
Yep I agree
They sound like Drunk Irishmen.
Is that for real retiring shares. Love it!! The rest of the market went haywire. Sold much lately not to get burned in the upper markets not here. Everyone here deserves a break for holding a shell with the pirate lol. 2 days huh, have some cash set aside :)
INO, NVAX, MRNA Darlings are down today. So is the Market.
Covid-19/Generex Receives 5M Contract From Four Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines
https://generex.com/index.html
World Health Org/Generex-EpiVax/Li Key Peptide Vaccine/PDF/Pg 2 https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1
NGIO/Generex Sub/S1 NASDAQ Upcoming Listing/Formerly Antigen Express/Website https://www.nugenerexdiagnostics.com/
------------------------------------------------------------------
Terms approved to proceed with collaborative effort with international consortium
MIRAMAR, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has received a contract from the China Technology Exchange, Beijing Zhonghua Investment Fund Management Co., LTD., Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development (Shenzhen) Co., LTD. The terms of the contract, which have been agreed to in writing by both parties, include an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced.
Joe Moscato, President & Chief Executive Officer of Generex has signed the draft contract with deal terms and will be traveling to China next week to sign the final, official contract with its Chinese partners to develop a COVID-19 vaccine using the Ii-Key immune system activation technology. Generex management will be presenting the company’s data, demonstrating the technology, and finalizing work plans with those partners to produce an Ii-Key-COVID-19 peptide vaccine that can be tested in human studies within 90 days. Mr. Moscato is expected to sign the official agreements on behalf of Generex at a signing ceremony in China next week, at which time Generex will make further announcements.
Mr. Moscato said, “Our subsidiary NuGenerex Immuno-Oncology (NGIO) "Future NASDAQ Listing" has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and a previous coronavirus, SARS. This wealth of experience has enabled us to develop a standardized protocol for rapid vaccine development, so we are positioned to respond in the event of a new, emerging pathogen. Our partners in China have recognized the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the COVID-19 epidemic, and we are excited to begin the work.”
https://www.pharmaceutical-technology.com/news/generex-covid-19-vaccine/
http://www.globenewswire.com/news-release/2020/02/27/1992098/0/en/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html
------------------------------------------------------------------
https://epivax.com/
Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic
Coronavirus nCOV-2019 antigenic epitopes predicted by EpiVax computational vaccinology and epitope prediction tools to be linked with Ii-Key to generate peptide vaccines against COVID-19
1. EpiVax will be using the the Covid-19 vaccine and will be developed using Generex’s li-Key immune system activation technology.
2. EpiVax worked for 21 years to be able to make a vaccine in 24 hours! (From EpiVax web site)
https://www.pharmaceutical-technology.com/news/generex-covid-19-vaccine/
3. EpiVax private biopharm company is working in collaborarion with Generex.
4. GNBT has signed a contract with EpiVax.
https://epivax.com/news/press-release-generex-signs-contract-with-epivax-to-develop-ii-key-peptide-vaccines-to-address-the-coronavirus-pandemic
5. EpiVax doing lab work both in Wuhan, China and Ross Labs at the University of Georgia.
6. EpiVax has solicited funds from NIH and has received funds from NIH in the past.
7. Generex will be doing human trials soon in China. Will test on human subjects who had the Covid-19 virus in the past. If successful, FDA will be under pressure to approve the vaccine fast.
8. This all translates to GNBT being a huge winner way ahead of the other labs.
-----------------------------------------------------------------
Biotech Stock News: Generex Biotechnology (OTCQB: GNBT) Announces Corporate Update and Investor Conference Call: Addressing the #Coronavirus Pandemic with Ii-Key Peptide Vaccines - Thursday February 13 https://www.investorideas.com/news/2020/biotech/02103OTCQBGNBT-Coronavirus.asp
-----------------------------------------------------------------
Generex Biotechnology Investing DD 2020
1) The CEO Joe Moscato is a marketing guy and he knows how to get everyone to see the big picture and to take long term views. Even if it means taking less pay now for rewards later. Including himself. No big fat salary for Joe now. In fact he has pretty much deferred any salary. What CEO does that?
2) GNBT filed an S-1 registration with the SEC with the future plans all noted. When the S-1 gets approved they have financing approved for a minimum of $40M to be used if needed. Think of it as a line of credit. The S-1 could be approved ANY day.
3) The financing allows them to purchase a majority interest privately held company named Altucell who may have a treatment which may cure Type 1 Diabetes. This companies research is fairly advanced and additional trials are about ready to go once funding arrives. Why?
from Generex: "as part of our due diligence
process, we pinpointed specific, comparable deals that validate the huge value of the
ALTuCELL acquisition, as evidenced by the recently announced purchase of Semma
Therapeutics by Vertex Pharmaceuticals for close to a billion dollars."
4) Generex is spinning off NGIO and it should be trading on the Nazdaq within a few weeks. It will be owned by Generex shareholders as we have been awarded dividend shares and ~70% by Generex. NGIO has the coronavirus vaccine to develop and a vaccine it is currently studying for breast cancer. Prostate research is underway as well. Other research is pending the new funding. Regarding number 4, I should have mentioned Merck. No doubt you all know about Keytruda being huge in cancer. The Generex/NGIO breast cancer study is a combo of NGIO's AE37 and Merck's Keytruda.
5) One of Generex's subs has a number of test kits for various ailments is working on a coronavirus test kit NOW.
6) Another sub, Olaregen has a wound care product being sold in the VA system and producing significant NEW revenue for Generex as of the last 3 months.
7) It was just announced two of the other subs have had a 400% increse in sales of their medical products recently
Over the next few day I will tell you about the MSO, HMO,Type 2 diabetes treatment and more.
Count yourselves lucky to be here now just before the good stuff is going to come together. Flippers will look back and regret having sold quite soon.
Did I mention Generex has already filed for UPLISTING ON THE NAZDAQ for GNBT? Waiting on the S-1 to be approved and the financing to be put to work.
Finally: I don't think many day traders and particularly short sellers realize what they have gotten themselves into. Any day now there will be news of significance such as the NGIO spinout and valuation details. Aside from cancer research and the rest, GNBT/NGIO is in position number one for a coronavirus vaccine in China. They are about to sign a nice deal with upfront money which is sufficient to get the initial work done in all likelihood. Milestone payment, all the costs covered and 20% of the rev's. NGIO's vaccine technology is such that it can be ready faster than traditional vaccines and can be produced in huge volumes very fast. A successful vaccine will result in an tremendous revenue revenue stream and big pharma looking at NGIO as a buy out candidate. A coronavirus vaccine is worth billions worldwide if this disease becomes an annual contagion as many medical researchers believe.
-----------------------------------------------------------------
6 Feb, 2020
Generex restarts vaccine efforts, Co-Diagnostics launches coronavirus test
Generex Biotechnology Corp. said two of its subsidiaries are collaborating with third-party groups and government agencies to reactivate efforts to develop vaccines against pandemic viruses.
The company previously developed vaccines for severe acute respiratory syndrome, or SARS, which became a global epidemic in 2003.
Generex' unit NuGenerex Immuno-Oncology — formerly Antigen Express — is looking at its patented Ii-Key technology to generate peptide vaccines. The technology is clinically proven to activate the immune system against a number of viruses such as H5N1 avian influenza or bird flu virus.
NuGenerex Immuno-Oncology said clinical trials of Ii-Key peptide vaccines have shown that the vaccines are safe and have long-lasting immune responses. One early-stage trial tested a series of vaccine peptides for H5N1 bird flu virus in more than 120 participants.
The Generex unit noted that its peptide vaccines could potentially be used against the novel coronavirus infection, or 2019-nCoV, because bird flu has been identified in animals in Wuhan, China, the epicenter of the 2019-nCoV outbreak.
NuGenerex Diagnostics, or NGIO, another Generex unit, has developed the Express II rapid diagnostic testing platform, which can detect antigens, antibodies or other components found in infectious diseases, cancer and other medical conditions. NGDx is initiating a project to adopt the platform that will help develop a diagnostic test for the Wuhan coronavirus infection.
Miramar, Fla.-based Generex Biotechnology, is an integrated healthcare holding company offering patient-centric care solutions such as rapid diagnosis and personalized therapies.
NuGenerex Immuno-Oncology, which is being spun out of Generex as a separate public company, has an ongoing mid-stage clinical trial investigating its lead cancer vaccine AE37 in combination with Merck & Co. Inc.'s Keytruda cancer drug for the treatment of triple-negative breast cancer.
Meanwhile, Co-Diagnostics Inc. said its CoPrimer diagnostic test for 2019-nCoV is available for sale to laboratories, hospitals and institutions that need a solution to the pandemic.
The company announced on Jan. 23 that CoPrimer, a polymerase chain reaction test designed for research purposes only, met the requirements for detecting coronavirus.
Co-Diagnostics CEO Dwight Egan said leveraging the company's proprietary design process and software has allowed it to quickly move the product from design to commercialization.
On Jan. 30, the World Health Organization declared the novel coronavirus a global health emergency. The U.S. Food and Drug Administration on Feb. 4 authorized the emergency use of in vitro diagnostic tests for the virus — those done on samples taken from the human body — due to its potential to negatively impact national security or public health.
Salt Lake City's Co-Diagnostics is a molecular diagnostics company that offers reagents used for diagnostic tests that can detect and analyze nucleic acid molecules.
------------------------------------------------------------------
https://www.newsbreak.com/info/generex-biotechnology-corporation
https://www.marketbeat.com/stocks/OTCMKTS/GNBT/
-----------------------------------------------------------------
https://www.modernreaders.com/news/2020/01/26/critical-review-soligenix-nasdaqsngx-vs-generex-biotechnology-nasdaqgnbt.html
Comparatively, 35.2% of Generex Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
----------------------------------------------------------------
$GNBT OVERLOOKED COVID-19 5M From China for Vaccine Development
World Health Org/Generex-EpiVax/Li Key Peptide Vaccine/PDF File Pg 2!!
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1
MIRAMAR, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has received a contract from the China Technology Exchange, Beijing Zhonghua Investment Fund Management Co., LTD., Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development (Shenzhen) Co., LTD. The terms of the contract, which have been agreed to in writing by both parties, include an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced.
Joe Moscato, President & Chief Executive Officer of Generex has signed the draft contract with deal terms and will be traveling to China next week to sign the final, official contract with its Chinese partners to develop a COVID-19 vaccine using the Ii-Key immune system activation technology. Generex management will be presenting the company’s data, demonstrating the technology, and finalizing work plans with those partners to produce an Ii-Key-COVID-19 peptide vaccine that can be tested in human studies within 90 days. Mr. Moscato is expected to sign the official agreements on behalf of Generex at a signing ceremony in China next week, at which time Generex will make further announcements.
Mr. Moscato said, “Our subsidiary NuGenerex Immuno-Oncology (NGIO) "Future NASDAQ Listing" has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and a previous coronavirus, SARS. This wealth of experience has enabled us to develop a standardized protocol for rapid vaccine development, so we are positioned to respond in the event of a new, emerging pathogen. Our partners in China have recognized the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the COVID-19 epidemic, and we are excited to begin the work.”
https://www.pharmaceutical-technology.com/news/generex-covid-19-vaccine/
https://investorshub.advfn.com/Generex-Biotechnology-Corp-GNBT-4711/
Thanks/Epivax update and others in the I-Box
The mortality rate is much higher than 1%. Also reports of younger people having problems. Lets hope clinical trials can happen sooner than later. I have heard human studies in 90 days looking in depth.
Most Lucrative Avenue is Anti Counterfeiting: Major conglomerates are interested viewing finely tuned quantum dots which emit a specific and un-copiable light signature which cannot be replicated and easily traced thru a supply chain.
World Health Org COVID-19 PDF File https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1
World Health Org COVID-19 PDF File https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1
MIRAMAR, Fla., March 04, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has signed a contract with EpiVax (https://epivax.com/) to use their computational tools to predict epitopes that can be used to generate peptide vaccines against the nCOV-2019 corona virus using the patented NuGenerex Immuno-Oncology(NGIO - Formerly Antigen Express) Ii-Key technology. EpiVax is a leader in computational vaccinology with expertise in epitope prediction, immune modulation, and dehumanized vaccine development. EpiVax has identified a number of “hotspots” in the amino acid sequences of the nCOV-2019 coronavirus proteins. Using the epitopes predicted by EpiVax, Generex will manufacture a series of synthetic amino acid peptides that mimic the epitopes of the virus and send them to China for testing. In collaboration with a team of researchers in China, Generex will test the reactivity of these peptides in blood samples that have been collected from patients who have recovered from COVID-19. Because these patients recovered from the coronavirus infection, their blood most likely contains immune cells and antibodies that recognize the peptides, proteins, and nucleic acids that represent antigenic epitopes of the virus. When the synthetic peptides are mixed with the blood samples, we can confirm that the sequences predicted by the EpiVax algorithms will be good vaccine peptides. Through a matrix assay that tests a series of peptides against the blood from recovered COVID-19 patients the team can select the best Ii-Key hybrid peptides to create a commercially viable vaccine that can proceed to human testing.
Dr. Eric von Hofe, PhD, Chief Scientific Officer of NGIO commented on the collaboration, “Both NuGenerex Immuno-Oncology and EpiVax have been on the forefront of peptide immunotherapy, and we have known Dr. De Groot and her excellent work on vaccines and the immune system for over 20 years. The combined efforts of our companies offer a world-class team of experts in the design of viral vaccines, and we are excited to deliver an effective vaccine solution that can limit the impact of the coronavirus epidemic.”
Dr. Anne De Groot, CEO & CSO of EpiVax endorsed the prospect of bringing a safe, effective vaccine to the clinic in collaboration with Generex, and added, "We've been preparing for this challenge for more than 20 years, and we are indeed ready to contribute our expertise to stop this global infectious disease as quickly as possible.” An interview in which Dr. De Groot spoke about her work with the coronavirus can be heard at this link:
https://www.wbur.org/commonhealth/2020/02/21/were-racing-time-biotechnology-companies-rush-to-complete-coronavirus-vaccine
Carol Nacy, Founder and CEO of Sequella, and a NGIO Board member who initiated the EpiVax collaboration said, “This collaboration demonstrates the extraordinary cooperation ongoing in the biopharma industry to quickly and effectively address the COVID-19 public health threat. The combination of EpiVax’s ability to rapidly identify critical peptides from the virus with NuGenerex’s proven platform for combining immunogenic peptides with a powerful adjuvant creates an exciting opportunity to address the challenges we are now experiencing with this new coronavirus.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
NuGenerex Immuno-Oncology (formerly Antigen Express), a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) is being spun out of Generex as a separate, independent public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer.
About EpiVax
EpiVax is a 21-year old privately held biotechnology company located in Providence, RI, with a broad portfolio of projects including vaccines and immunotherapies for infectious diseases, autoimmunity and cancer. Scientists at EpiVax, led by co-founders Annie De Groot, MD and Bill Martin, lead the field in immunogenicity risk assessment. The ISPRI and iVAX toolkits for therapeutics and vaccines are used by a global roster of companies. Visit www.epivax.com for more information.
Facts Matter.
Most Lucrative Avenue is Anti Counterfeiting: Major conglomerates are interested viewing finely tuned quantum dots which emit a specific and un-copiable light signature which cannot be replicated and easily traced thru a supply chain.
Headline: GNBT Generex Receives Contract from Four Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines
GNBT is Getting Seriously Interesting Turnaround OTC Biotech Company with lots of subs. Besides their turnaround and S1 (2 NASDAQ uplistings) the Corona thing just landed on their lap. Read on
Generex has Funding, Covad/19 Chinese Contract, Royalties, Recent Articles and WHO Recognition. The CHINESE SIGN A CONTRACT with GENEREX THIS IS HUGE when you sit back and realize the only thing holding this back is "what you tell me" This company is being looked at as an OTC Shell LOL. Its a lot more than people realize with many subs. This shell will burst onto the NASDAQ Times 2 Leading with NGIO. Fact: Covid/19 plays have been runners in recent days. You know what else I hope Generex can lead the way to make an effective vaccine. This is some serious sh"t.
LOOKS SOLID for NGIO: Our subsidiary NuGenerex Immuno-Oncology (NGIO) "Future NASDAQ Listing" has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and a previous coronavirus, SARS. This wealth of experience has enabled us to develop a standardized protocol for rapid vaccine development, so we are positioned to respond in the event of a new, emerging pathogen. Our partners in China have recognized the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the COVID-19 epidemic, and we are excited to begin the work.”
Worth Lot more than 80 cents worth. Fuzzy rapid numbers upward may come into play very soon.
GNBT Generex Receives Contract from Four Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=154104505
Clarify: 2 NASDAQ Uplistings not 1
GNBT
NGIO
Lot more than 80 cents worth. Fuzzy rapid numbers upward may come into play very soon. Besides their turnaround and S1 uplistings the Corona thing just landed on their lap.
Our partners in China have recognized the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the COVID-19 epidemic, and we are excited to begin the work.”
Generex has Funding, Covad/19 Chinese Contract, Royalties, Recent Articles and WHO Recognition. The CHINESE SIGN A CONTRACT with GENEREX THIS IS HUGE when you sit back and realize the only thing holding this back is "what you tell me" This company is being looked at as an OTC Shell LOL. Its a lot more than people realize with many subs. This shell will burst onto the NASDAQ Times 2 Leading with NGIO. Fact: Covid/19 plays have been runners in recent days. You know what else I hope Generex can lead the way to make an effective vaccine. This is some serious sh"t.
LOOKS SOLID for NGIO: Our subsidiary NuGenerex Immuno-Oncology (NGIO) "Future NASDAQ Listing" has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and a previous coronavirus, SARS. This wealth of experience has enabled us to develop a standardized protocol for rapid vaccine development, so we are positioned to respond in the event of a new, emerging pathogen. Our partners in China have recognized the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the COVID-19 epidemic, and we are excited to begin the work.”
Adding/Slappin last couple of days